Summary: In 104 adults with type 2 diabetes, a slower flexible semaglutide titration regimen (starting at 0.0675 mg with weekly increments and delays for symptoms) was compared with label-recommended titration over 26 weeks. Withdrawal due to gastrointestinal adverse events was lower with flexible titration (2% vs 19%, P=0.005), while HbA1c and BMI changes were similar between arms. This open-label pilot signals better tolerability and adherence without demonstrating improved glycaemic efficacy.
PICO Summary
| Element | Detail |
|---|---|
| Population | 104 adults with type 2 diabetes; randomized controlled open-label pilot study, single-centre (Israel). |
| Intervention | Flexible slower titration: starting 0.0675 mg (five dose-selector clicks), gradual increases of 0.0675 mg/week with delays for gastrointestinal adverse events, over 26 weeks (flexible arm). |
| Comparison | Label-recommended titration: 0.25 mg, 0.5 mg, then 1 mg at 4-week intervals (label arm). |
| Outcome | Withdrawal due to gastrointestinal adverse events: 2% (flexible) vs 19% (label), P=0.005. Nausea 45.1% vs 64.2%, P=0.051 (not statistically significant). Asthenia 9.8% vs 24.5%, P=0.047. Days with nausea 2.88 vs 6.3, P=0.017. HbA1c and BMI changes similar between groups. No CI, ARR/NNT, or powered efficacy endpoint reported for this pilot. |
Slower semaglutide titration vs label regimen
RCT pilot · type 2 diabetes · 26 weeks
Slower, symptom-guided titration cut GI-driven withdrawals from 19% to 2% with comparable HbA1c and BMI. A tolerability and adherence signal, not proof of better glycaemic efficacy.
Expert Commentary
This randomized open-label pilot tested a pragmatic question that clinicians face daily: whether a gentler, symptom-guided semaglutide titration reduces the early gastrointestinal burden that drives discontinuation. The verdict is a cautiously positive tolerability signal. Treatment withdrawal due to gastrointestinal events fell from 19% to 2% (P=0.005), and asthenia and the number of nausea-days were also reduced, while final doses, HbA1c, and BMI were comparable between arms. The honest reading is that slower titration improved adherence and tolerability without compromising, or improving, glycaemic efficacy; the reduction in overall nausea incidence (45.1% vs 64.2%) did not reach statistical significance (P=0.051). Several limitations temper the findings. As a pilot study of only 104 patients, it was not powered for efficacy, and the open-label design is susceptible to reporting bias for subjective symptoms such as nausea, which is precisely the primary signal here. The five-click starting protocol is also off-label and operationally fiddly. Can I use this with my patients? Cautiously yes for the patient who has previously abandoned a GLP-1 receptor agonist because of nausea; a slower, symptom-paced up-titration is a reasonable individualized strategy, though it remains hypothesis-generating rather than guideline-endorsed. A larger blinded trial with prespecified adherence endpoints would help confirm whether this approach should become standard practice.
References
Eldor R, Avraham N, Rosenberg O, Shpigelman M, Golan-Cohen A, Cukierman-Yaffe T, Merzon E, Buch A. Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care. 2025;48(9):1607-1611. doi:10.2337/dc25-0690